AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Sangamo discontinues SB509 development following disappointing study data.
(From Pharma)
M2PHARMA-October 4, 2011-Sangamo discontinues SB-509 development following disappointing study data (C)2011 M2 COMMUNICATIONS http://www.m2.com
4 October 2011 - US Sangamo BioSciences Inc (NASDAQ:SGMO) said on Monday that its Phase IIb trial of SB-509 did not meet its primary or secondary clinical endpoints in subjects with moderate severity diabetic neuropathy (DN) as compared to placebo.
Based on these data, Sangamo will terminate further development of SB-509 and will focus on its pipeline of ZFP Therapeutics for HIV and monogenic …
